Naar inhoud

Merck

MRK

NYSE · Healthcare · US

US$ 115,48
US$ 1,61 (+1,41%)
Koersverloop (90 dagen) Bron: Yahoo Finance
Dag laag/hoog
US$ 113,00 – US$ 115,63
52w laag/hoog
US$ 76,66 – US$ 125,14
Marktwaarde
US$ 285,22 mld
Volume
10.492.472

Waardering

K/W (TTM)
32,53
K/W (verwacht)
12,06
Winst per aandeel
US$ 3,55
Koers/boekwaarde
6,22
Bèta
0,22

Kerncijfers

Omzet (TTM)
US$ 65,77 mld
EBITDA
US$ 29,52 mld
Winstmarge
13,59%
Rendement eigen verm. (ROE)
18,94%
Omzetgroei
4,90%
Uitstaande aandelen
2.469.824.415

Dividend

Dividendrendement
2,94%
Dividend p/a
US$ 3,40
Uitkeringsratio
93,52%

Over Merck

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Koersen en cijfers zijn indicatief en kunnen vertraagd zijn. Deze pagina is informatief en vormt geen beleggingsadvies.